Cynosure, Inc. stock performance trend indicates that the stock price has rallied 51.2% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 29.56% . Looking at the past 52 week period, the stock price is up at 60.12% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Cynosure, Inc. has a positive value of 9.11 compared to overall market.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 75.55.
Cynosure, Inc. (NASDAQ:CYNO) has tumbled 0.08% during the past week and has dropped 0.38% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.31%. Cynosure, Inc. (NASDAQ:CYNO) has underperformed the index by 1.51% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Company shares have received an average consensus rating of Hold for the current week Cynosure, Inc. (NASDAQ:CYNO) witnessed a volatile trading activity on Friday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $66 and reached the intraday high at $66.05. The bulls started the profit booking and pushed the shares to intraday low of $65.95. The trading session was marked by a volume range of 1,465,541 shares exchanging hands. The 52-week high of the shares is $66.65 and the 52-week low is $38.01. The market cap of the company stands at $1,607 million and there are 24,351,449 shares in public circulation.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Cynosure was Downgraded by Maxim Group on Feb 14, 2017 to Hold, Price Target of the shares are set at $66.
Company has reported several Insider transactions to the SEC, on Nov 22, 2016, Douglas J Delaney (Executive VP, Sales) sold 7,875 shares at 45.00 per share price.On Nov 22, 2016, Michael R Davin (Chairman, President and CEO) sold 16,284 shares at 45.00 per share price.On Sep 1, 2016, Brian M. Barefoot (director) sold 21,000 shares at 51.66 per share price.
Cynosure Last issued its quarterly earnings results on Feb 7, 2017. The company reported $0.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $0.41. The company had revenue of $122.10 million for the quarter, compared to analysts expectations of $119.97 million. The companys revenue was up 19.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.42 EPS.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosures products incorporate a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag and diode lasers, as well as intense pulsed light.